Performance Restriction Sample Clauses

POPULAR SAMPLE Copied 1 times
Performance Restriction. The Performance Restriction shall be satisfied based on three separate Performance Periods, as provided in the table below. Each “Performance Period” shall be a designated calendar year and, taken together, the three Performance Periods make up a three-year period known as the “Measurement Period”, which starts on January 1, 2021 and ends on December 31, 2023. In order for the Units scheduled to vest during a Performance Period to satisfy the Performance Restriction, the Committee must determine that the Company has achieved 6.75% or greater Pre-Tax Margin (defined below) in at least two calendar quarters during such Performance Period. This determination shall occur during the ninety (90) day period following the end of each Performance Period. January 1, 2021 to December 31, 2021 33.33% January 1, 2022 to December 31, 2022 33.33% January 1, 2023 to December 31, 2023 33.34% For purposes of this Agreement, the following definitions shall apply:
Performance Restriction. In order for the Units to vest, the Committee must determine that the Company has achieved 4.5% or greater Adjusted Pre-Tax Margin (defined below) in at least three calendar quarters of any of the next seven calendar quarters starting April 1, 2024 (the “Performance Restriction”). The seven calendar quarters beginning April 1, 2024, and ending December 31, 2025 are defined as the (“Measurement Period”). This determination shall occur during the ninety (90) day period following the end of the Measurement Period. For purposes of this Agreement, the following definitions shall apply:
Performance Restriction. Subject to the other provisions of this Section 19, Performer is restricted from engaging in any scope of work activity that involves human subject or animal subject research. Likewise, Performer may not use or submit invoice for any award funding to carry out any human subject or animal subject research until this written notice is received. Failure to obtain appropriate human or animal subject research approval may result in termination of agreement. For clarity, no research involving human subjects may occur, and individuals shall not be enrolled in such research, without prior approval by the Office for Human Research Protection (OHRP) of an assurance to comply with the requirements of 45 CFR Part 46 to protect human research subjects. If funding was provided on the understanding that human subject research would eventually occur with funding provided, the awardee institution bears the ultimate responsibility for protecting human subjects under the award. Compliance for all performance sites must be ensured by the awardee. The Performer must 1) obtain a Federal-wide Assurance (FWA) of Protection for Human Subjects from the Office for Human Research Protection (OHRP), 2) obtain initial and continuing approval (if required) of the research by an appropriately constituted and registered Institutional Review Board (IRB), and 3) submit the full IRB approved package (including protocol, IRB approval letter, any required training certificates, etc.). For instructions on registering IRBs, obtaining FWAs, and completing Human Subjects Education requirements, see the OHRP website at: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/ohrp. In order to remove this restriction, Performer shall submit evidence of the required FWA and IRB approval package to the PM and BID. When all of the required documentation has been reviewed and approved by the Government, the Agreements Officer (AO) of CMF will lift the restriction via written notification.
Performance Restriction. In order for the Restricted Stock to vest, the Compensation Committee of the Board of Directors of the Company (the “Committee”) must determine that [the Company has achieved [•] (the “Performance Restriction”). The [•] calendar quarters starting [•] and ending [•] are referred to as the “Measurement Period.” “